Biotechnology is rapidly becoming a pillar of national power. The nation that can discover, test, and deploy new therapies most efficiently will not only improve the health of its citizens but also shape global standards, attract investment, strengthen military readiness, and dominate one of the most important industries of the past century.
China understands this reality. Beijing has made biotechnology a strategic priority and is investing aggressively in artificial intelligence, synthetic biology, advanced biomanufacturing, gene therapies, and precision medicine.
America retains critical advantages, but in key measures of the race, China has already pulled ahead. China now conducts more early-stage clinical trials than the United States, and in 2025, Chinese companies captured nearly half of global pharmaceutical licensing activity by dollar amount. The bipartisan National Security Commission on Emerging Biotechnology has warned that the U.S. risks losing its advantage entirely if it fails to act. In many ways, biotechnology is now a Sputnik moment — and the race is already underway.
Success in this competition depends on one factor above all: speed. Scientific discovery means little if promising therapies remain locked in development for years. The nation that can move most rapidly from laboratory benches to patients will attract scientific talent, investment capital, and manufacturing capacity while establishing the standards that others follow. Real-time clinical development is therefore much more than a regulatory innovation — it is a strategic capability.
